Prioritization of cancer therapeutic targets using CRISPR–Cas9 screensFiona M. Behan, Mathew J. Garnett, Francesco Iorio et al.|Nature|2019Cited by 1.4k
MET signalling: principles and functions in development, organ regeneration and cancerLivio Trusolino, Paolo M. Comoglio|Nature Reviews Molecular Cell Biology|2010Cited by 1.2k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Giovanna Marrapese et al.|The Lancet Oncology|2016Cited by 1k
A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal CancerAndrea Bertotti, Livio Trusolino|Cancer Discovery|2011Cited by 948
The genomic landscape of response to EGFR blockade in colorectal cancerAndrea Bertotti, Victor E. Velculescu, Eniko Papp et al.|Nature|2015Cited by 495